ProCE Banner Activity

CE / CME

Addressing Key Questions: Expert Insights to Guide Pathologist-Informed Clinical Decisions in HER2-Expressing or Amplified Solid Tumors

Video

This on-demand webcast aims to provide expert insight to guide pathologist-informed clinical decisions in patients with HER2-expressing or amplified solid tumors.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

ABPath MOC: maximum of 1.00 Lifelong Learning point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 10, 2024

Expiration: April 09, 2025

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Katherine M. Bever

Katherine M. Bever, MD

Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Laura C. Collins

Laura C. Collins, MD

Vice Chair of Anatomic Pathology
Director of Breast Pathology
Beth Israel Deaconess Medical Center
Professor of Pathology
Harvard Medical School
Boston, Massachusetts

Tanya Gupta

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Alexander Craig Mackinnon, Jr.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Funda Meric-Bernstam

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth D. Thompson

Elizabeth D. Thompson, MD, PhD

Associate Professor of Pathology and Oncology
Division of Surgical Pathology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, and Seagen.

AstraZeneca

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals

Seagen

Target Audience

This educational program is intended for pathologists and other healthcare professionals involved in precision care of HER2-altered solid tumors.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence and competence, of learners to accurately perform pathological assessment, diagnose and provide evidence-based treatment strategies for patients with HER2-altered solid tumor malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement pathological procedures to identify patients who may benefit from HER2-targeted therapy through proper understanding of HER2 status across solid tumors and the use of guideline- and expert-recommended testing

  • Summarize the importance of proper HER2 evaluation through consideration of current and emerging clinical trial data and recent FDA-approved indications with HER2-targeted therapies

  • Collaborate with the multidisciplinary team to reduce barriers to pathological assessment and optimize therapeutic strategies for patients with HER2-altered solid tumors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD: consultant/advisor/speaker: Bayer, Pfizer.

Katherine M. Bever, MD

Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Katherine M. Bever, MD: researcher: Bristol Myers Squibb, Merck Sharpe & Dohme.

Laura C. Collins, MD

Vice Chair of Anatomic Pathology
Director of Breast Pathology
Beth Israel Deaconess Medical Center
Professor of Pathology
Harvard Medical School
Boston, Massachusetts

Laura C. Collins, MD, has no relevant financial relationships to disclose.

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Tanya Gupta, MD: consultant/advisor/speaker: AstraZeneca, Biotheranostics, Gilead, Pfizer.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA, has no relevant financial relationships to disclose.

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Funda Meric-Bernstam, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Calibr (Scripps), Daiichi Sankyo, Dava Oncology, EcoR1, Eisai, Exelixis, GT Apeiron, Incyte, Infinity, Karyopharm, LegoChem Bio, Lengo Therapeutics, Menarini, OnCusp, Protai Bio, Seagen, Tallac Therapeutics, Theratechnologies, Zentalis, Zymeworks; researcher (paid to institution): Aileron Therapeutics, AstraZeneca, Bayer, Calithera Bioscience, Healthcare Pharmaceuticals.

Elizabeth D. Thompson, MD, PhD

Associate Professor of Pathology and Oncology
Division of Surgical Pathology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Elizabeth D. Thompson, MD, PhD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 10, 2024, through April 09, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

American Board of Pathology Continuing Certification

A blue and white microscopeDescription automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning points in the American Board of Pathology’s Continuing Certification Program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

For ABPath Lifelong Learning points, your information will be shared with the ABPath through CCO’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your Lifelong Learning points to appear on your ABPath records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).